Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.

Zhang J, Xian TZ, Wu MX, Li C, Pan Q, Guo LX

Cardiovascular diabetology25 Apr 2020Cited by 27 (Europe PMC)

PMID32334592PMCIDPMC7183674DOI10.1186/s12933-020-01014-7PepBankPUB-32334592

Summary

BackgroundExenatide, a glucagon like peptide 1 analog, has been suggested to reduce the cardiovascular disease risk factors, such as body weight, blood pressure and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). This was the first randomized, open-label, controlled trial to compare the effects of exenatide versus insulin on subclinical atherosclerosis, as assessed by carotid-intima media thickness (CIMT), in patients with T2DM.MethodsA total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks. The primary endpoint was change from baseline in CIMT, and secondary endpoints included changes at week 52 from baseline in body weight, glycemic markers, lipid metabolism markers, blood pressure, C-reactive protein, fibrinogen, 8-hydroxydeoxyguanosine, irisin, and brain natriuretic peptide.ResultsExenatide more significantly reduced the CIMT from baseline compared with insulin after 52 weeks, with a mean difference of - 0.14 mm (95% interval confidence: - 0.25, - 0.02; P = 0.016). Weight and body mass index were both significantly reduced in the exenatide group over 52 weeks. Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40. Correlation analyses showed that CIMT was positively correlated with low-density lipoprotein cholesterol.ConclusionsTwice-daily exenatide could prevent atherosclerosis progression in patients with T2DM over a 52-week treatment period compared with insulin therapy. Trial registration Chinese Clinical Trial Registry ChiCTR-1800015658.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced carotid intima-media thickness more than insulin.
In plain wordsIn patients with diabetes, exenatide reduced carotid artery wall thickness more than insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCarotid intima-media thickness
Study
n = 66
Comparator
Aspartate 70/30 insulin
Analysis
Primary
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
CIMT mean difference
−0.14 mm
versus insulin
Source sentences
Summary
Exenatide more significantly reduced the CIMT from baseline compared with insulin after 52 weeks, with a mean difference of - 0.14 mm (95% interval confidence: - 0.25, - 0.02; P = 0.016).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks.
Show in the study text Report a problemFND-3233459201
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced total lipoprotein more than insulin at weeks 16 and 40.
In plain wordsIn patients with diabetes, exenatide reduced total lipoprotein more than insulin at weeks 16 and 40.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal lipoprotein at weeks 16 and 40
Study
n = 66
Comparator
Aspartate 70/30 insulin
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks.
Show in the study text Report a problemFND-3233459204
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced LDL cholesterol more than insulin at weeks 16 and 40.
In plain wordsIn patients with diabetes, exenatide reduced LDL cholesterol more than insulin at weeks 16 and 40.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLDL cholesterol at weeks 16 and 40
Study
n = 66
Comparator
Aspartate 70/30 insulin
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks.
Show in the study text Report a problemFND-3233459205
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, weight decreased significantly in the exenatide group over treatment.
In plain wordsIn patients with diabetes, weight decreased significantly from baseline in the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Weight and body mass index were both significantly reduced in the exenatide group over 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks.
Show in the study text Report a problemFND-3233459202
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, BMI decreased significantly in the exenatide group over treatment.
In plain wordsIn patients with diabetes, BMI decreased significantly from baseline in the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Weight and body mass index were both significantly reduced in the exenatide group over 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks.
Show in the study text Report a problemFND-3233459203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords